Login to Your Account

Lack Of 'Strong Efficacy Signal' In Celacade Trial Hurts Vasogen

By Jennifer Boggs

Wednesday, August 31, 2005
Shares of Vasogen Inc. tumbled more than 40 percent after the company said it was stopping the Phase III SIMPADICO trial of its Celacade technology in patients with symptomatic peripheral arterial disease (PAD). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription